search
Back to results

A Study of Dulaglutide in Chinese Participants

Primary Purpose

Diabetes Mellitus, Type 2, Healthy Volunteers

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Dulaglutide
Placebo
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

All Participants:

  • Native Chinese (all 4 grandparents of Chinese origin)
  • Male participants with female partners of child-bearing potential, or partners who are pregnant or breastfeeding, agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator.
  • The method of contraception may be one of the following: condom with spermicidal agent, male participant sterilization, true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable).
  • Female participants not of child-bearing potential (i.e. are postmenopausal or permanently sterilized [e.g. tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli international units per milliliter (mIU/mL).
  • Female participants who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment.

Participants with T2DM:

  • Have T2DM controlled with diet or exercise alone or with a single oral agent antihyperglycemic medication (OAM) (metformin, sulfonylureas, meglitinides, acarbose [or other disaccharidase inhibitors] or thiazolidinediones) for at least 3 weeks (3 months for thiazolidinediones) before admission. Note that participants receiving sulfonylureas, meglitinides or acarbose may participate only if this treatment is stopped and metformin substituted. If switched to metformin, participants should be allowed to stabilize on metformin for 3 weeks before receiving study drug.
  • If T2DM controlled with diet or exercise alone, must have a hemoglobin A1c (HbA1c) value of 6.5% to 10.5% at screening and a fasting blood glucose value of 126 to 250 milligrams per deciliter (mg/dL) (approximately 7.0 to 13.9 millimoles per liter [mmol/L]) at screening.
  • If T2DM controlled with OAM(s), must have an HbA1c value of 9.0% or less at screening and a fasting blood glucose value of 110 to 200 mg/dL (approximately 6.1 to 11.1 mmol/L) at screening. If a participant's T2DM is being controlled with OAM(s) other than metformin, the participant's OAM will be stopped for at least 3 weeks before administration of study drug.

Exclusion Criteria:

All Participants:

  • Have a history or presence of cardiovascular (myocardial infarction, cerebrovascular accident, venous thromboembolism), respiratory, hepatic, renal, hematological, neurological autoimmune or endocrine (except T2DM), disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Have evidence of significant active neuropsychiatric disease.
  • Have poorly controlled hypertension (systolic >160 millimeters of mercury [mmHg] and/or diastolic >100 mmHg) and/or evidence of labile blood pressure including symptomatic postural hypotension.
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric empty (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-4 inhibitors. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician.
  • Have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC.

Participants with T2DM

  • Have experienced outpatient use of insulin for control of diabetes within the past 6 months.
  • Have clinically significant peripheral vascular occlusive disease in the opinion of the investigator.
  • Have known severe exudative diabetic retinopathy in the opinion of the investigator.
  • Have known significant autonomic neuropathy as evidenced by urinary retention, diabetic diarrhea, or gastroparesis.
  • Have experienced a ketoacidotic episode (pH less than 7.3) requiring hospitalization in the last 6 months.
  • Regular use of drugs that affect the glycodynamics and that directly reduce gastrointestinal motility (eg, anticholinergics, antispasmodics, 5HT3 antagonists, dopamine antagonists, and opiates) and of systemic corticosteroids by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption.

Sites / Locations

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

0.5 mg Dulaglutide (Part A-Healthy)

0.75 mg Dulaglutide (Part A-Healthy)

1.5 mg Dulaglutide (Part A-Healthy)

Placebo (Part A-Healthy)

0.5 mg Dulaglutide (Part B-T2DM)

0.75 mg Dulaglutide (Part B-T2DM)

1.5 mg Dulaglutide (Part B-T2DM)

Placebo (Part B-T2DM)

Arm Description

0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods

0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods

1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods

Placebo administered once SQ to healthy participants in 1 of 3 treatment periods

0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks

0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks

1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks

Placebo administered to participants with T2DM once weekly SQ for 4 weeks

Outcomes

Primary Outcome Measures

Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Pharmacokinetics: Half-life of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.

Secondary Outcome Measures

Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])
Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.

Full Information

First Posted
August 15, 2012
Last Updated
February 8, 2016
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01667900
Brief Title
A Study of Dulaglutide in Chinese Participants
Official Title
Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks. Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Healthy Volunteers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
0.5 mg Dulaglutide (Part A-Healthy)
Arm Type
Experimental
Arm Description
0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
Arm Title
0.75 mg Dulaglutide (Part A-Healthy)
Arm Type
Experimental
Arm Description
0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
Arm Title
1.5 mg Dulaglutide (Part A-Healthy)
Arm Type
Experimental
Arm Description
1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
Arm Title
Placebo (Part A-Healthy)
Arm Type
Placebo Comparator
Arm Description
Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
Arm Title
0.5 mg Dulaglutide (Part B-T2DM)
Arm Type
Experimental
Arm Description
0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
Arm Title
0.75 mg Dulaglutide (Part B-T2DM)
Arm Type
Experimental
Arm Description
0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
Arm Title
1.5 mg Dulaglutide (Part B-T2DM)
Arm Type
Experimental
Arm Description
1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
Arm Title
Placebo (Part B-T2DM)
Arm Type
Placebo Comparator
Arm Description
Placebo administered to participants with T2DM once weekly SQ for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Dulaglutide
Other Intervention Name(s)
LY2189265
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Primary Outcome Measure Information:
Title
Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide
Description
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time Frame
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Title
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide
Description
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time Frame
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Title
Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide
Description
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time Frame
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Title
Pharmacokinetics: Half-life of Dulaglutide
Description
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time Frame
Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Secondary Outcome Measure Information:
Title
Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])
Description
Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.
Time Frame
Baseline and Days 3, 24, and 29

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All Participants: Native Chinese (all 4 grandparents of Chinese origin) Male participants with female partners of child-bearing potential, or partners who are pregnant or breastfeeding, agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator. The method of contraception may be one of the following: condom with spermicidal agent, male participant sterilization, true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable). Female participants not of child-bearing potential (i.e. are postmenopausal or permanently sterilized [e.g. tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli international units per milliliter (mIU/mL). Female participants who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment. Participants with T2DM: Have T2DM controlled with diet or exercise alone or with a single oral agent antihyperglycemic medication (OAM) (metformin, sulfonylureas, meglitinides, acarbose [or other disaccharidase inhibitors] or thiazolidinediones) for at least 3 weeks (3 months for thiazolidinediones) before admission. Note that participants receiving sulfonylureas, meglitinides or acarbose may participate only if this treatment is stopped and metformin substituted. If switched to metformin, participants should be allowed to stabilize on metformin for 3 weeks before receiving study drug. If T2DM controlled with diet or exercise alone, must have a hemoglobin A1c (HbA1c) value of 6.5% to 10.5% at screening and a fasting blood glucose value of 126 to 250 milligrams per deciliter (mg/dL) (approximately 7.0 to 13.9 millimoles per liter [mmol/L]) at screening. If T2DM controlled with OAM(s), must have an HbA1c value of 9.0% or less at screening and a fasting blood glucose value of 110 to 200 mg/dL (approximately 6.1 to 11.1 mmol/L) at screening. If a participant's T2DM is being controlled with OAM(s) other than metformin, the participant's OAM will be stopped for at least 3 weeks before administration of study drug. Exclusion Criteria: All Participants: Have a history or presence of cardiovascular (myocardial infarction, cerebrovascular accident, venous thromboembolism), respiratory, hepatic, renal, hematological, neurological autoimmune or endocrine (except T2DM), disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. Have evidence of significant active neuropsychiatric disease. Have poorly controlled hypertension (systolic >160 millimeters of mercury [mmHg] and/or diastolic >100 mmHg) and/or evidence of labile blood pressure including symptomatic postural hypotension. Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric empty (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-4 inhibitors. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician. Have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC. Participants with T2DM Have experienced outpatient use of insulin for control of diabetes within the past 6 months. Have clinically significant peripheral vascular occlusive disease in the opinion of the investigator. Have known severe exudative diabetic retinopathy in the opinion of the investigator. Have known significant autonomic neuropathy as evidenced by urinary retention, diabetic diarrhea, or gastroparesis. Have experienced a ketoacidotic episode (pH less than 7.3) requiring hospitalization in the last 6 months. Regular use of drugs that affect the glycodynamics and that directly reduce gastrointestinal motility (eg, anticholinergics, antispasmodics, 5HT3 antagonists, dopamine antagonists, and opiates) and of systemic corticosteroids by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM- 5 PM Eastern time (UTC/GMT -5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
City
Beijing
ZIP/Postal Code
100034
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
34787823
Citation
Xu J, Zhang Y, Li Y, Zhao X, Zhou W, Loghin C, Tham LS, Cui X, Cui Y, Wang W. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study. Adv Ther. 2022 Jan;39(1):488-503. doi: 10.1007/s12325-021-01921-5. Epub 2021 Nov 17.
Results Reference
derived

Learn more about this trial

A Study of Dulaglutide in Chinese Participants

We'll reach out to this number within 24 hrs